Routine PIK3CA testing from tissue or ctDNA isolated from plasma samples from patients with HR+/HER2– advanced/mBC is now recommended, as patients with PIK3CA-mutated breast cancer may be appropriate candidates for alpelisib, a recently FDA approved selective inhibitor of the α isoform of PI3Ki [42]. Here, HR is linked to breast carcinoma.